文献速递免疫规划传染病防控与疫情报告

抗羊快疫、羊黑疫、羔羊痢疾与肠毒血症的多价亚单位疫苗研制

Development of a genetically engineered multivalent subunit vaccine against "struck", "braxy", lamb dysentery, and enterotoxemia in sheep.
PubMed 文献 · Vaccine · 2026-09-29

本研究构建了编码梭菌α毒素与β毒素基因的pET-32a-α-β1质粒,与表达α-β2-ε三价融合蛋白的质粒分别在大肠杆菌DE3中诱导表达并纯化。两种重组蛋白按1:1混合冻干,以氢氧化铝佐剂复溶后免疫绵羊,确定0.2 mg混合蛋白为最小免疫剂量;免疫后21天血清可中和产气荚膜梭菌B、C、D型及腐败梭菌毒素,免疫羊对上述毒素攻击的存活率为100%,阴性对照组为0%。

要点

  • 0.2 mg混合蛋白被确定为该亚单位疫苗的最小免疫剂量。
  • 免疫后21天血清中和产气荚膜梭菌B、C、D型毒素及腐败梭菌毒素的能力分别为10、10、27、9倍小鼠致死剂量。
  • 免疫羊对产气荚膜梭菌B、C、D型及腐败梭菌毒素攻击的存活率为100%,阴性对照组为0%。

核心结论

  • 编码腐败梭菌α毒素与产气荚膜梭菌β毒素基因的重组亚单位疫苗候选物,在绵羊中可诱导针对产气荚膜梭菌B、C、D型及腐败梭菌毒素的中和抗体并提供100%保护。

研究设计与样本

  • 构建pET-32a-α-β1质粒,与已构建的pET-32a-α-β2-ε质粒分别转化大肠杆菌DE3,经异丙基-β-D-硫代半乳糖苷诱导表达重组蛋白。
  • 重组蛋白α-β1与α-β2-ε纯化后按蛋白浓度比1:1混合并冻干,用氢氧化铝佐剂复溶,以不同剂量免疫绵羊。
  • 依据免疫羊抗体滴度与血清中和滴度确定最小免疫剂量,并在免疫后21天进行毒素中和试验。

主要发现

  • 0.2 mg混合蛋白被确定为该亚单位疫苗的最小免疫剂量。
  • 免疫后21天,免疫羊血清分别中和10、10、27、9倍小鼠致死剂量的产气荚膜梭菌B、C、D型毒素及腐败梭菌毒素。
  • 所有免疫羊均抵抗产气荚膜梭菌B、C、D型及腐败梭菌毒素攻击,存活率100%;阴性对照组存活率0%。

关键数值与推荐

  • 最小免疫剂量:0.2 mg混合蛋白。
  • 免疫后21天血清中和能力:产气荚膜梭菌B型10倍、C型10倍、D型27倍小鼠致死剂量,腐败梭菌毒素9倍小鼠致死剂量。
  • 攻毒保护:免疫羊存活率100%,阴性对照组存活率0%。

临床怎么用

  • 该多价亚单位疫苗候选物可在绵羊中同时针对产气荚膜梭菌B、C、D型及腐败梭菌提供免疫保护,为后续疫苗开发提供依据。
  • 0.2 mg混合蛋白可作为后续免疫剂量探索的参考起点。

局限性

  • 原文为摘要,未报告样本量、具体免疫程序细节及统计学比较结果。
  • 保护效果仅基于免疫后21天的攻毒试验,未报告长期免疫持续时间或田间有效性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The development of genetically engineered multivalent subunit vaccines is needed to provide protection against infections caused by Clostridium septicum and multiple types of Clostridium perfringens. In this study, a pET-32a(+) plasmid encoding the C. septicum α-toxin gene and the C. perfringens β-toxin gene was constructed; a positive clone was designated pET-32a-α-β1. This plasmid, along with pET-32a-α-β2-ε-previously engineered to express a C. perfringens α-β2-ε trivalent recombinant chimeric fusion protein-was transformed into Escherichia coli DE3 for recombinant protein expression after isopropyl-β-D-thiogalactopyranoside induction. Recombinant proteins α-β1 and α-β2-ε were purified, mixed at a protein concentration ratio of 1:1, and subsequently freeze-dried. The freeze-dried proteins were reconstituted with an aluminum hydroxide adjuvant and administered to sheep at various doses. Based on antibody titers and serum neutralization titers in immunized sheep, 0.2 mg of mixed protein was identified as the minimum immunization dose for the subunit vaccine. Toxin neutralization tests performed 21 days post-vaccination showed that sera from immunized sheep neutralized 10, 10, 27, and nine times the mouse lethal doses of C. perfringens types B, C, and D, and C. septicum toxins, respectively. All immunized sheep were protected against C. perfringens types B, C, and D, and C. septicum toxins, with a survival rate of 100%; the negative control group showed a survival rate of 0%. These encouraging findings provide a foundation for the development of novel subunit vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Zhao JH, Ma QL, Wang WB, et al. Development of a genetically engineered multivalent subunit vaccine against "struck", "braxy", lamb dysentery, and enterotoxemia in sheep. Vaccine. 2026. PMID: 42810174. doi:10.1016/j.vaccine.2026.129207

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。